An experimental determination in Calspan Ludwieg tube of the base environment of the integrated space shuttle vehicle at simulated Mach 4.5 flight conditions (test IH5 of model 19-OTS)

A model test program was conducted to determine heat transfer and pressure distributions in the base region of the space shuttle vehicle during simulated launch trajectory conditions of Mach 4.5 and pressure altitudes between 90,000 and 210,000 feet. Model configurations with and without the solid propellant booster rockets were examined to duplicate pre- and post-staging vehicle geometries. Using short duration flow techniques, a tube wind tunnel provided supersonic flow over the model. Simultaneously, combustion generated exhaust products reproduced the gasdynamic and thermochemical structure of the main vehicle engine plumes. Heat transfer and pressure measurements were made at numerous locations on the base surfaces of the 19-OTS space shuttle model with high response instrumentation. In addition, measurements of base recovery temperature were made indirectly by using dual fine wire and resistance thermometers and by extrapolating heat transfer measurements

High pressure pre-treatments promote higher rate and degree of enzymatic hydrolysis of cellulose

The effect of high pressure (HP) pre-treatments on the subsequent enzymatic hydrolysis of cellulose from bleached kraft Eucalyptus globulus pulp by cellulase from Tricoderma viride was evaluated. Pressure pre-treatments of 300 and 400 MPa during 5–45 min, lead to both an increased rate and degree of hydrolysis, reaching values ranging from 1.5- to 1.9-fold, quantified by the formation of reducing sugars. Both the pressure and time under pressure influenced the enzymatic hydrosability of the cellulosic pulps, with the former being more important. The results indicate that the pressure pre-treatments promoted an increased accessibility of cellulose towards cellulase in the cell wall. The results obtained open promising possibilities, to contribute to overcome conventional limitations of enzymatic cellulose hydrolysis for the production of fermentable glucose, for the production of second generation bioethanol and chemicals by enhancement of both rate and yield of hydrolysis. The results are also of interest for the preparation of “pressure engineered” celullose with incremented tailored hydrolysis patterns

Technoeconomic and life-cycle analysis of single-step catalytic conversion of wet ethanol into fungible fuel blendstocks

Technoeconomic and life-cycle analyses are presented for catalytic conversion of ethanol to fungible hydrocarbon fuel blendstocks, informed by advances in catalyst and process development. Whereas prior work toward this end focused on 3-step processes featuring dehydration, oligomerization, and hydrogenation, the consolidated alcohol dehydration and oligomerization (CADO) approach described here results in 1-step conversion of wet ethanol vapor (40 wt% in water) to hydrocarbons and water over a metal-modified zeolite catalyst. A development project increased liquid hydrocarbon yields from 36% of theoretical to >80%, reduced catalyst cost by an order of magnitude, scaled up the process by 300-fold, and reduced projected costs of ethanol conversion 12-fold. Current CADO products conform most closely to gasoline blendstocks, but can be blended with jet fuel at low levels today, and could potentially be blended at higher levels in the future. Operating plus annualized capital costs for conversion of wet ethanol to fungible blendstocks are estimated at $2.00/GJ for CADO today and$1.44/GJ in the future, similar to the unit energy cost of producing anhydrous ethanol from wet ethanol ($1.46/GJ). Including the cost of ethanol from either corn or future cellulosic biomass but not production incentives, projected minimum selling prices for fungible blendstocks produced via CADO are competitive with conventional jet fuel when oil is$100 per barrel but not at $60 per barrel. However, with existing production incentives, the projected minimum blendstock selling price is competitive with oil at$60 per barrel. Life-cycle greenhouse gas emission reductions for CADO-derived hydrocarbon blendstocks closely follow those for the ethanol feedstock

Micro-Hall Magnetometry Studies of Thermally Assisted and Pure Quantum Tunneling in Single Molecule Magnet Mn12-Acetate

We have studied the crossover between thermally assisted and pure quantum tunneling in single crystals of high spin (S=10) uniaxial single molecule magnet Mn12-acetate using micro-Hall effect magnetometry. Magnetic hysteresis experiments have been used toinvestigate the energy levels that determine the magnetization reversal as a function of magnetic field and temperature. These experiments demonstrate that the crossover occurs in a narrow (~0.1 K) or broad (~1 K) temperature interval depending on the magnitude and direction of the applied field. For low external fields applied parallel to the easy axis, the energy levels that dominate the tunneling shift abruptly with temperature. In the presence of a transverse field and/or large longitudinal field these energy levels change with temperature more gradually. A comparison of our experimental results with model calculations of this crossover suggest that there are additional mechanisms that enhance the tunneling rate of low lying energy levels and broaden the crossover for small transverse fields.Comment: 5 pages, 5 figure

A two-stage pneumatic repeating pellet injector for refueling magnetically confined plasmas in long-pulse fusion experiments

An experiment to demonstrate the feasibility of a repetitive pneumatic pellet injector at 1 Hz in the velocity range of 2 to 3 knVs was carried out in a collaboration between Oak Ridge National Laboratory and ENEA Frascati, in the context of a cooperative agreement between the US Department of Energy and EURATOM-ENEA Association. The third round of this experiment was completed in May 1995. Both the operation and performance of the equipment were improved, and the original objectives of the collaboration have been met. The facility was also briefly operated with neon pellets to explore the potential for producing fast ``killer`` pellets for disruption amelioration applications. Speeds of 1.7 km/s were achieved using a piston mass of 43 g. Higher speeds should be achievable with a system specifically designed for neon or other higher Z gases. Finally, tests were performed with thin boron carbide coatings (2 {mu}m) on the Ergal pistons. The test results were encouraging because piston friction was reduced was the piston wear

Simulation of a Shear Coaxial GO2/GH2 Rocket Injector with DES and LES Using Flamelet Models

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/97098/1/AIAA2012-3744.pd

Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an autosomal recessive motor neuron disease affecting children. It is caused by mutations in the IGHMBP2 gene (11q13) and presently has no cure. Recently, adeno-associated virus serotype 9 (AAV9)-mediated gene therapy has been shown to rescue the phenotype of animal models of another lower motor neuron disorder, spinal muscular atrophy 5q, and a clinical trial with this strategy is ongoing. We report rescue of the disease phenotype in a SMARD1 mouse model after therapeutic delivery via systemic injection of an AAV9 construct encoding the wild-type IGHMBP2 to replace the defective gene. AAV9-IGHMBP2 administration restored protein levels and rescued motor function, neuromuscular physiology, and life span (450% increase), ameliorating pathological features in the central nervous system, muscles, and heart. To test this strategy in a human model, we transferred wild-type IGHMBP2 into human SMARD1-induced pluripotent stem cell-derived motor neurons; these cells exhibited increased survival and axonal length in long-term culture. Our data support the translational potential of AAV-mediated gene therapies for SMARD1, opening the door for AAV9-mediated therapy in human clinical trials